Immunovant (IMVT) market cap
Immunovant (IMVT) has a market cap of $6.86B. At the end of fiscal 2026 (March 31, 2026) its market cap was $4.53B. That is 74.9% higher than the $2.59B of fiscal 2025. Today's figure is 51.5% above the fiscal 2026 year-end. Figures as of 19 Nov 2026, 03:10 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Market cap today
- $6.86B
- Market cap, fiscal 2026
- $4.53B
- Change on fiscal 2025
- +74.9%
- Growth, 5 years
- +26.3% a year
- Highest on record
- $4.53Bfiscal 2026
- Lowest on record
- $604.33Mfiscal 2022
- Fiscal years on record
- 62021–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Immunovant market cap, in more detail
Over the five fiscal years to 2026 the market cap grew at a compound 26.3% a year. Across the 6 fiscal year-ends on record (2021–2026), the highest was $4.53B in fiscal 2026 and the lowest $604.33M in fiscal 2022.
Market cap at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Immunovant market cap, year by year
| Fiscal year | Market cap | Change | Year ended | Share price at year-end | Diluted shares |
|---|---|---|---|---|---|
| Today | $6.86B | — | $33.17 | — | |
| 2026 | $4.53B | 74.9% up | $24.84 | 182.42M | |
| 2025 | $2.59B | 41.9% down | $17.09 | 151.57M | |
| 2024 | $4.46B | 133.7% up | $32.31 | 138.10M | |
| 2023 | $1.91B | 215.9% up | $15.51 | 123.08M | |
| 2022 | $604.33M | 57.1% down | $5.51 | 109.68M | |
| 2021 | $1.41B | — | $16.04 | 87.76M | |
| 2020 | — | — | $15.56 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote.
How to read it
It is what the stock market says the whole company is worth — a measure of size, not of whether the shares are cheap or dear.
Immunovant, figure by figure
- Immunovant revenue
- Immunovant earnings
- Immunovant earnings per share (EPS)
- Immunovant P/E ratio
- Immunovant P/S ratio
- Immunovant P/B ratio
- Immunovant free cash flow
- Immunovant operating margin
- Immunovant dividend
- Immunovant shares outstanding
- Immunovant total debt
- Immunovant cash on hand
- Immunovant total assets
- Immunovant total liabilities
- Immunovant net assets (shareholders' equity)
- Immunovant return on equity (ROE)
- Immunovant return on invested capital (ROIC)
Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value
Immunovant market cap: questions and answers
What is Immunovant's market cap?
Immunovant (IMVT) has a market cap of $6.86B. At the end of fiscal 2026 (March 31, 2026) its market cap was $4.53B. That is 74.9% higher than the $2.59B of fiscal 2025.
What is the growth rate of Immunovant's market cap?
Over the five fiscal years to 2026 the market cap grew at a compound 26.3% a year.
What are the highest and lowest market cap figures on record for Immunovant?
Across the 6 fiscal year-ends on record (2021–2026), the highest was $4.53B in fiscal 2026 and the lowest $604.33M in fiscal 2022.
How is Immunovant's market cap calculated?
Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote. For Immunovant it is on record here for 6 fiscal years, 2021 to 2026.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: market cap
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Immunovant (IMVT) market cap”, data as of 19 November 2026. https://funkfolio.com/stock/IMVT/market-cap
Underlying data: the company's filings with the SEC and Yahoo Finance.